Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SciBase Holding ABOSTO:SCIB +1.45%47 Equity-to-Asset is 0.56 as of Mar. 2026, which is 26% below its 10-year median of 0.76. GuruFocus rates OSTO:SCIB with a GF Score™ of 47/100 and a GF Value™ of kr20.19 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 854 Medical Devices & Instruments companies, SciBase Holding AB ranks worse than 60.89% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. SciBase Holding AB's Total Stockholders Equity for the quarter that ended in Mar. 2026 was kr58.12 Mil. SciBase Holding AB's Total Assets for the quarter that ended in Mar. 2026 was kr103.69 Mil.
Therefore, SciBase Holding AB's Equity to Asset Ratio for the quarter that ended in Mar. 2026 was 0.56.
The historical rank and industry rank for SciBase Holding AB's Equity-to-Asset or its related term are showing as below:
OSTO:SCIB'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.13 Med: 0.76 Max: 0.93
Current: 0.56
During the past 13 years, the highest Equity to Asset Ratio of SciBase Holding AB was 0.93. The lowest was 0.13. And the median was 0.76.
OSTO:SCIB's Equity-to-Asset is ranked worse than 60.89% of 854
companies
in the Medical Devices & Instruments industry
Industry Median: 0.64
vs OSTO:SCIB: 0.56
SciBase Holding AB (OSTO:SCIB) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
SciBase Holding AB Equity-to-Asset Related Terms
SciBase Holding AB Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for SciBase Holding AB's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:SCIB vs ABT, SYK, MDT: Equity-to-Asset Comparison
For the Medical Devices subindustry, SciBase Holding AB's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SciBase Holding AB Equity-to-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, SciBase Holding AB's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where SciBase Holding AB's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
SciBase Holding AB's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SciBase Holding AB (OSTO:SCIB) has a Equity-to-Asset of 0.56 as of Mar. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on SciBase Holding AB and its competitors. This is 26% below median its historical median of 0.76. Over the past decade, SciBase Holding AB's Equity-to-Asset has ranged from 0.13 to 0.93. According to the industry distribution chart, SciBase Holding AB ranks #520 out of 854 companies in the Medical Devices & Instruments industry, placing it in the top 60.9%.
Is SciBase Holding AB's Equity-to-Asset too high?
SciBase Holding AB's current Equity-to-Asset of 0.56 is 26% below median its 10-year median of 0.76. Over the past 10 years, this metric has ranged from a low of 0.13 to a high of 0.93. The Medical Devices & Instruments industry median Equity-to-Asset is 0.64. SciBase Holding AB's value of 0.56 is 12.5% below this industry median. Based on the distribution chart, SciBase Holding AB ranks #520 out of 854 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, SciBase Holding AB has a GF Score™ of 47/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does SciBase Holding AB's Equity-to-Asset compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, SciBase Holding AB ranks #520 out of 854 companies for Equity-to-Asset. This places SciBase Holding AB in the lower half of its industry. The industry median Equity-to-Asset is 0.64. SciBase Holding AB's value of 0.56 is 12.5% below this benchmark. Historically, SciBase Holding AB's own Equity-to-Asset has ranged from 0.13 to 0.93 over the past decade. While the company's 10-year median is 0.76 vs. the industry median of 0.64, SciBase Holding AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Medical Devices & Instruments company?
The median Equity-to-Asset among Medical Devices & Instruments companies is 0.64, based on 854 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SciBase Holding AB's current Equity-to-Asset of 0.56 is 12.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on SciBase Holding AB and its competitors. For the Medical Devices & Instruments industry, the median Equity-to-Asset is 0.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SciBase Holding AB's current Equity-to-Asset is 0.56, which is 26% below median its own 10-year median of 0.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SciBase Holding AB stock overvalued right now?
Based on GuruFocus' analysis, SciBase Holding AB (OSTO:SCIB) is currently considered Significantly Overvalued. The stock's GF Value™ is kr20.19, compared to a current price of kr27.90 — trading 38.2% above its estimated fair value. The current Equity-to-Asset is 0.56, which is 26% below median its 10-year median of 0.76 and 12.5% below the Medical Devices & Instruments industry median of 0.64. SciBase Holding AB's overall GF Score™ is 47/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For SciBase Holding AB (OSTO:SCIB), the current Equity-to-Asset is 0.56 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SciBase Holding AB (OSTO:SCIB) Overvalued in 2026?
Based on GuruFocus' analysis, SciBase Holding AB stock appears to be overvalued.
The current stock price of kr27.90 is trading 38.2% above its estimated GF Value™ of kr20.19.
GuruFocus considers SciBase Holding AB to be Significantly Overvalued.
Key valuation signals for OSTO:SCIB:
Equity-to-Asset: 0.56 (26% below median its 10-year median of 0.76)
GF Value™: kr20.19 vs. price of kr27.90 (38.2% above fair value)
Industry Position: 12.5% below the Medical Devices & Instruments median (#520 of 854)
No single metric tells the full story. See the OSTO:SCIB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SciBase Holding AB is a medical technology company specializing in early detection of skin cancer and prevention in dermatology. SciBase develops, manufactures, and commercializes Nevisense, a point-of-care technology platform that combines AI (artificial intelligence) and EIS technology to elevate diagnostic accuracy and support the prevention of skin diseases. The company's product portfolio consists of the Nevisense platform technology for multiple clinical applications and proprietary Nevisense electrodes. The products are based on measurements using electrical impedance spectroscopy (EIS), analysed using custom artificial intelligence (AI)-based algorithms. The company operates in two segments, which include skin cancer and skin barrier assessment.
47GF Score
Get the complete analysis for OSTO:SCIB
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:SCIB has been successfully added to your 
